EC
TYRA icon

Elmind Capital’s Tyra Biosciences TYRA Stock Holding History

Elmind Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Sell
20,000
-330,000
-94% -$10.9M 0.16% 34
2026
Q1 		$13.4M Hold
350,000
– – 3.81% 10
2025
Q4 		$9.2M Buy
+350,000
New +$6.43M 2.72% 13

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Elmind Capital's TYRA Position: Q2 2026 in Review

Elmind Capital reduced its Tyra Biosciences (TYRA) stake by 94% in Q2 2026, selling an estimated $10.9M and leaving 20,000 shares worth $639K. The position accounts for 0.16% of the portfolio, ranked #34.

Elmind Capital first reported a position in TYRA in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.4M in Q1 2026. 170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Elmind Capital held 20,000 shares of Tyra Biosciences worth $639K as of Q2 2026.
  • Elmind Capital sold 330,000 Tyra Biosciences shares in Q2 2026, an estimated $10.9M.
  • Tyra Biosciences made up 0.16% of Elmind Capital's portfolio in Q2 2026, its #34 holding.
  • Elmind Capital first reported a position in Tyra Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Elmind Capital's Tyra Biosciences position peaked at $13.4M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.